Fluidigm Corporation (Nasdaq:FLDM), an innovative
biotechnology tools provider with a vision to improve life through
comprehensive health insight, today announced a collaboration with
Bethyl Laboratories to provide broader verified antibody access for
researchers using Fluidigm’s Imaging Mass Cytometry™ (IMC™)
technology.
“Tools for understanding the immune system are
more important than ever as researchers work to improve human
health, particularly in responding to challenges posed by
COVID‑19,” said Andrew Quong, PhD, Chief Science Officer of
Fluidigm. “With Bethyl’s leadership in specialized antibodies and
our expertise in high-multiplex imaging technology, this
collaboration will provide our customers with critically needed new
research capabilities.”
Bethyl Laboratories has a portfolio of more than
9,500 primary and secondary antibodies, including the recombinant
monoclonal antibodies that are well-suited for imaging studies.
Through the new collaboration, antibody products manufactured by
Bethyl will be verified on the Hyperion™ Imaging System and offered
to Fluidigm customers.
“At Bethyl, we are committed to supporting
scientific discovery and facilitating a deeper understanding of the
human immune system and are pleased to collaborate with a partner
that is dedicated to the same goals,” said John Carwile, MD, Chief
Executive Officer of Bethyl Laboratories. “The agreement with
Fluidigm will expand the accessibility of our antibody products,
increase the power of Fluidigm’s IMC technology, and in turn, drive
meaningful insights into health and disease research.”
Fluidigm currently offers more than 100
pathologist-verified metal‑conjugated Maxpar® antibodies for use
with IMC, including antibodies verified for use with both
formalin-fixed, paraffin-embedded (FFPE) and frozen tissues. These
preconjugated antibodies enable researchers to obtain highly
multiplexed images of a large number of sample types.
With the additional offerings through Bethyl,
Fluidigm will provide access to a collection of antibodies that
will increase in number over time and branch into new research
areas for IMC.
“Imaging Mass Cytometry has revolutionized
translational and clinical research in cancer, immuno-oncology, and
immune-mediated diseases, and is now deployed on the front lines in
state‑of‑the‑art research into the human immune response to
COVID-19,” said Chris Linthwaite, Fluidigm President and CEO. “Deep
and meaningful insights from diverse biomarkers with potential
diagnostic, prognostic, or therapeutic value are at the heart of
what our IMC technology brings to the table, and this significant
addition to the library of available antibodies provides an
unparalleled research capability in high-parameter tissue
imaging.
“We are excited to collaborate with Bethyl to
strengthen our IMC value proposition at this critical moment in
global health and disease research.”
About
FluidigmFluidigm (Nasdaq:FLDM) focuses on the most
pressing needs in translational and clinical research, including
cancer, immunology, and immunotherapy. Using proprietary CyTOF® and
microfluidics technologies, we develop, manufacture, and market
multi-omic solutions to drive meaningful insights in health and
disease, identify biomarkers to inform decisions, and accelerate
the development of more effective therapies. Our customers are
leading academic, government, pharmaceutical, biotechnology, and
plant and animal research laboratories worldwide. Together with
them, we strive to increase the quality of life for all. For more
information, visit fluidigm.com.
Fluidigm, the Fluidigm logo, CyTOF,
Hyperion, Imaging Mass Cytometry, IMC, and Maxpar are trademarks
and/or registered trademarks of Fluidigm
Corporation in the United States and/or other
countries. All other trademarks are the sole property of their
respective owners. Fluidigm products are provided for Research Use
Only. Not for use in diagnostic procedures.
About Bethyl LaboratoriesBethyl
Laboratories, Inc., has been dedicated to supporting scientific
discovery through its qualified antibody products and custom
polyclonal antibody services since its founding in 1972. Currently,
Bethyl’s portfolio consists of over 9,500 catalog products;
offering over 8,200 primary antibodies targeting over 3,300
proteins and 1,300 secondary antibodies raised against
immunoglobulins from over 25 species.
With over 45 years of experience, Bethyl is also
a leading provider of custom polyclonal antibody production
services. Bethyl offers complete packages from initial peptide
synthesis to affinity purification of custom polyclonal antibodies
from an antigen-specific immunosorbent. Most recently, our
capabilities have expanded, and we now offer contract recombinant
rabbit monoclonal antibody partnerships.
Forward-Looking Statements for
FluidigmThis press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, including, among others, statements regarding
the anticipated benefits of a collaboration for research and
availability of new products resulting from such collaboration.
Forward-looking statements are subject to numerous risks and
uncertainties that could cause actual results to differ materially
from currently anticipated results, including but not limited to
risks relating to the potential adverse effects of the coronavirus
pandemic on resource availability and business and operating
results during 2020; challenges inherent in developing,
manufacturing, launching, marketing, and selling new products;
uncertainties in contractual relationships; risks relating to
company research and development, sales, marketing, and
distribution plans and capabilities; reductions in research and
development spending or changes in budget priorities by customers;
interruptions or delays in the supply of components or materials
for, or manufacturing of, Fluidigm products; seasonal variations in
customer operations; potential product performance and quality
issues; intellectual property risks; and competition. Information
on these and additional risks and uncertainties and other
information affecting Fluidigm business and operating
results is contained in Fluidigm’s Annual Report on Form 10-K for
the year ended December 31, 2019, and in its other filings
with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date
hereof. Fluidigm disclaims any obligation to update these
forward-looking statements except as may be required by law.
Available InformationWe use our
website (fluidigm.com), investor site (investors.fluidigm.com),
corporate Twitter account (@fluidigm), Facebook page
(facebook.com/Fluidigm), and LinkedIn page
(linkedin.com/company/fluidigm-corporation) as channels of
distribution of information about our products, our planned
financial and other announcements, our attendance at upcoming
investor and industry conferences, and other matters. Such
information may be deemed material information, and we may use
these channels to comply with our disclosure obligations under
Regulation FD. Therefore, investors should monitor our website and
our social media accounts in addition to following our press
releases, SEC filings, public conference calls, and webcasts.
Contacts: Media: Mark Spearman
Senior Director, Corporate Communications 650 243 6621
mark.spearman@fluidigm.com
Investors: Agnes Lee Vice President, Investor
Relations 650 416 7423 agnes.lee@fluidigm.com
Fluidigm (NASDAQ:FLDM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Fluidigm (NASDAQ:FLDM)
Historical Stock Chart
From Sep 2023 to Sep 2024